XGEVA sol inj 120 mg/1.7ml flac 1.7 ml
7680618650014
CH-61865
M05BX04
07.16.1.
Reimbursement limitations:
XGEVA3
Remboursement pour les patients atteints de tumeurs solides présentant des métastases osseuses, en association avec …
1 / 3
google
Details
- Product number
- 6186501
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- denosumabum 120 mg, sorbitolum 78.1 mg, polysorbatum 20, acidum aceticum glaciale aut natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 1.7 ml corresp. natrium 0.7 mg.
Articles (1)
XGEVA 120 mg, Injektionslösung
Injektionslösung
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
120.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
78.1 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
0.7 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 429.50
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/03/2012
Authorization holder
Amgen Switzerland AG
6343 Risch
Authorization information
- Swissmedic authorization number
- 61865
- Drug name
- XGEVA, Injektionslösung
- Galenic form
- LSPA
- ATC Code
- M05BX04
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 02/12/2011
- Authorization expiration date
- 31/12/9999
- IT number
- 07.16.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- XGEVA sol inj 120 mg/1.7ml flac 1.7 ml
- Description (DE)
- XGEVA Inj Lös 120 mg/1.7ml Durchstf 1.7 ml
- Market launch
- 02/12/2011
- Narcotic (BTM)
- No